Filgrastim (G-CSF)

🧮 Dose calculator

Febrile neutropenia (empiric therapy) · Regimen source: FDA Neupogen · 2.1

• • Start at least 24 h after chemotherapy; continue until ANC >10,000 after the nadir (up to 2 weeks). May increase by 5 mcg/kg each cycle. CBC twice weekly. FDA Neupogen · 2.1

Enter age and weight.

👥 Special populations

• 🤰 PregnancyUse with caution

  Label: available data have not established an association with birth defects, miscarriage or adverse outcomes. FDA Neupogen · 8.1

  “Available data from published studies, including several observational studies of pregnancy outcomes in women exposed to filgrastim products and those who were unexposed, have not established an association with NEUPOGEN use during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Neupogen · 8.2

  “Risk Summary There is published literature documenting transfer of filgrastim into human milk.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Neupogen · 8.4

  “The safety and effectiveness of NEUPOGEN have been established in pediatric patients with SCN [see Clinical Studies (14.5) ] .”

• 👴 Older adultsNo specific problem stated

  Label: no specific difference or dose adjustment stated for older adults. FDA Neupogen · 8.5

  “No overall differences in safety or effectiveness were observed between these subjects and younger subjects.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.